疟疾和镰状细胞病治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00030125
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 420
Buy Now

【研究报告】2022年疟疾和镰状细胞病治疗市场规模为44.5715亿美元,预计到2030年将达到291.796亿美元;据估计,从 2022 年到 2030 年,复合年增长率将达到 26.5%。
市场洞察和分析师观点:
属于疟原虫属的寄生虫会导致疟疾,这是一种潜在的致命疾病。雌性按蚊的叮咬会传播这种寄生虫。在东南亚、中南美洲以及撒哈拉以南非洲等疟疾最容易发生的地区也能发现这种病毒。尽管有五种疟原虫可以感染人类,但恶性疟原虫 (P. falciparum) 和间日疟原虫 (P. vivax) 是引起疟疾疾病的最常见原因。某些红细胞异常随着时间的推移而发生变化,以减轻疟疾的严重程度。镰状细胞性状是红细胞疾病之一,人会产生正常和异常的血红蛋白。
增长动力:
疟疾是急性发热性疾病之一,由疟原虫引起,并通过感染者传播雌性按蚊。人类体内的五种寄生虫主要引起疟疾,其中两种——恶性疟原虫和间日疟原虫——被认为是对人类健康的最大威胁。此外,恶性疟原虫是最致命的疟疾寄生虫,在非洲大陆传播最广泛。此外,间日疟原虫是撒哈拉以南非洲以外大多数国家的主要疟疾寄生虫。根据世界卫生组织 (WHO) 最新发布的《2020 年世界疟疾报告》(WMR),全球报告了 2.41 亿例疟疾病例,而 2019 年记录的病例数为 2.27 亿例。疟疾造成的死亡人数每年增加 69,000 人。其中大约三分之二(即 47,000 人)是由于 COVID-19 爆发期间医疗服务中断造成的;其余三分之一的死亡人数,即 22,000 人,反映了世界卫生组织计算疟疾死亡率的方法最近发生的变化(不考虑 COVID-19 的干扰)。
世界卫生组织非洲区域在全球疟疾负担中所占比例很高。 2020 年,全球约 95% 的疟疾病例和约 96% 的死亡发生在非洲,约 80% 的死亡病例为 5 岁及以下儿童。据世界卫生组织称,尼日利亚、坦桑尼亚、刚果民主共和国和莫桑比克这四个非洲国家的疟疾相关死亡人数约占全球报告的一半。根据《2020 年柳叶刀区域卫生》报告,非洲国家的疟疾负担最高;恶性疟原虫是导致 5 岁以下儿童死亡率最高的一个重要原因,占全世界 77%;在非洲国家,恶性疟原虫占疟疾儿童死亡率的 96%。间日疟原虫占疟疾病例总数的 2%(450 万),主要来自亚洲。根据《WMR 2021》,东南亚国家记录了约 2% 的全球疟疾负担,其中印度占 2020 年估计疟疾病例的 83% 和与疟疾相关的死亡人数的 82%。
镰刀型疟疾的治疗计划细胞疾病(SCD)可分为两类:维持健康和治疗并发症。镰状细胞性贫血具有基于血红蛋白基因独特突变的基因型和表型变异。该疾病在全球范围内发病率很高,而且严重程度也在上升。据世界卫生组织称,世界上大约5%的人口具有抑制血红蛋白疾病(如镰状细胞性贫血和地中海贫血)的基因。根据国家医学图书馆发表的一项关于镰状细胞病的研究,每年有超过 300,000 名婴儿出生时患有严重的血红蛋白疾病;此外,预计到 2050 年将有 40 万新生儿患有镰状细胞病。此外,根据美国血液学会 2023 年发布的报告,估计美国患有 SCD 的人数约为 7 万至 10 万。因此,全球不同地区疟疾和镰状细胞病患病率的上升促进了疟疾和镰状细胞病治疗市场的增长。
战略见解
报告细分和范围:
疟疾和镰状细胞病治疗市场根据治疗、给药途径、分销渠道和地理位置进行细分。根据治疗方法,市场分为疟疾和镰状细胞病。从给药途径来看,疟疾和镰状细胞病治疗市场分为口服和肠胃外。根据分销渠道,市场分为直接招标、医院药店、零售药店、网上药店等。疟疾和镰状细胞病治疗市场根据地理位置分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、西班牙和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国和亚太地区其他地区)、中东和非洲(阿联酋、沙特阿拉伯、非洲、尼日利亚、刚果、坦桑尼亚、乌干达、加纳、肯尼亚、赞比亚以及中东和非洲其他地区) ),以及南美洲和中美洲(巴西、阿根廷以及南美洲和中美洲其他地区)。
细分分析:
疟疾和镰状细胞病治疗市场按治疗方法分为疟疾和镰状细胞病。 2022年,疟疾细分市场占据了更大的市场份额,预计2022年至2030年该细分市场的复合年增长率为28.5%。恶性疟原虫主要引起疟疾。疟疾不能直接在人与人之间传播;只有受感染的蚊子叮咬才能将寄生虫转移到血液中并传播到肝脏。氯喹(也称为磷酸氯喹)是一种在美国只能通过处方购买的抗疟药,以 Aralen 品牌销售,也是一种仿制药。奎宁于 1820 年从金鸡纳树皮中分离出来,是第一个被鉴定的抗疟药。世卫组织建议使用 RTS、S/AS01(RTS、S)疟疾疫苗来预防儿童疟疾。加纳、肯尼亚和马拉维正在进行的试点计划的结果为第一种疟疾疫苗的建议提供了依据。试点四年后,自 2019 年以来,已有约 150 万名儿童接种了第一剂疟疾疫苗。
按给药途径划分的疟疾和镰状细胞病治疗市场 – 2022 年和 2030 年
按给药途径,疟疾和镰状细胞病治疗市场分为口服和肠胃外治疗。 2022年,口服细分市场占据更大的市场份额,预计注射细分市场在预测期内将录得更快的复合年增长率。口服给药是最理想、最合适的给药途径,因为它具有较高的患者依从性、非侵入性、最少的无菌限制、成本效益、剂型设计的灵活性以及制造过程的简便性。易于给药和长期成本效益等优点是推动口服药物采用的主要因素。胶囊、片剂和其他口服药物的低制造成本推动了疟疾和镰状细胞病治疗市场的增长。一些可用的抗疟疾药物包括奎宁、奎尼丁、氯喹、阿莫地喹、他非诺喹、氯胍、氯丙胍和青蒿素。基于青蒿素的联合疗法(ACT)和联合疗法正在用于治疗由恶性疟原虫引起的单纯性疟疾。 ACT 是目前市场上最有效的抗疟药物。
根据分销渠道,疟疾和镰状细胞病治疗市场分为直接招标、医院药房、零售药房、在线药房等。直接招标部分在 2022 年占据最大的市场份额。招标是履行特定职责或提供固定金额物品的要约。在招标程序的第一步中,承包商将被要求提交密封的施工标书或在特定时限内提供特别计划的服务或产品。印度的电子招标程序旨在确保政府或特定客户的工作及时完成。例如,有些地方可能有具体的采购法规,规定如何做出决策以及接受哪些投标。例如,全印度医学科学研究所 (AIIMS) 邀请经验丰富、信誉良好且财务状况良好的公司、机构和公司投标来自印度不同医疗机构的疟疾检测试剂盒和药物。过去三年从事类似业务并向中央/州政府/知名私立医院或自治机构提供相同服务的人可以将其技术和商业投标放在密封信封中发送。
区域分析:
根据地理位置,疟疾和镰状细胞病治疗市场分为五个关键地区:北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。到 2022 年,北美将在全球市场中占据重要份额。根据美国疾病控制与预防中心 (CDC) 的数据,美国每年报告约 2,000 例疟疾病例,其中大部分是来自其他国家的旅行者和移民。孕妇和 5 岁以下儿童感染疟疾和患严重疾病的风险最高。由于能够在美国传播疟疾的按蚊(媒介)的耐力,疟疾传播可能在美国恢复的永久风险。
根据全球基金 2022 年 4 月的数据,与疟疾相关的病例和死亡人数增长主要是由于资金延迟和 COVID-19 大流行造成的中断。然而,正如 2022 年 9 月全球基金报告中提到的那样,减轻这些影响的努力已取得进展。美国政府为控制疟疾所做的努力包括主要通过美国总统疟疾倡议 (PMI) 开展的活动,该倡议由美国全球疟疾委员会监督协调员。根据全球卫生政策,2022 财年美国用于疟疾控制和研究活动的资金约为 10 亿美元。美国政府 2021-2026 年 PMI 战略的目标是努力减少疟疾造成的死亡并降低疟疾发病率,正在接近其消除的长期目标。
在美国,大量非裔美国人患有镰状细胞病。自 2006 年以来,美国所有州都强制要求通过血液检测对新生儿进行 SCD 筛查。根据 CDC 的研究“镰状细胞病相关死亡率在 COVID-19 大流行期间似乎更高”,2014 年至 2019 年美国 SCD 相关死亡率保持稳定;但 2020 年,该国记录了 1,023 例与 SCD 相关的死亡,与 2014-2019 年期间的死亡率相比增加了 12%。根据美国血液学会 2023 年发布的数据,约有 70,000-100,000 名美国人患有镰状细胞病,这是最常见的遗传性血液疾病。因此,美国疟疾和镰状细胞病治疗市场的增长是由疟疾和 SCD 患者数量不断增加推动的。
行业发展和未来机遇:
全球疟疾和镰状细胞疾病领域的主要参与者采取的各种举措镰状细胞病治疗市场如下:
2022 年 11 月,诺华和 Medicines for Malaria Venture (MMV) 宣布决定进入新型非青蒿素组合治疗单纯性疟疾的 3 期研究。这种新颖的组合还含有一种优化的苯芴醇配方,使其可以每天给药一次,而不是通常的每日两次给药。 2022 年 10 月,辉瑞公司收购了 Global Blood Therapeutics Inc.。GBT 带来了一个有潜力的产品组合和管道。满足这个服务不足的社区的全方位关键需求。 GBT 发现并开发了 Oxbryta (voxelotor),这是一种直接针对 SCD 根本原因的一流药物。竞争格局和主要公司:
Cipla Ltd、Pfizer Inc、Sun Pharmaceutical Industries Ltd、Sanofi SA、GSK Plc 、诺华公司、辉瑞公司、Emmaus Life Sciences Inc、AdvaCare Pharma USA LLC、VLP Therapeutics LLC 和 Lupin Ltd 是主要的疟疾和镰状细胞病治疗公司。这些公司专注于新技术、现有产品的进步以及地域扩张,以满足全球不断增长的消费者需求。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is meant by the malaria and sickle cell disease treatment market?

Malaria is a serious infection spread by an infected mosquito. The infection is very common in certain parts of the world, such as large areas of Africa and Asia, Central and South America, and the Dominican Republic and Haiti. However, malaria is an entirely preventable and treatable disease if tackled at an early stage. For example, malaria is treated with a prescription drug to kill the parasite. The types of drugs and the length of treatment vary depending on the type of malarial parasite infection, the severity of symptoms, and age.

Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help prevent complications related with the disease. SCD is identified with a simple blood test. In addition, SCD can be detected while the baby is in the womb. Diagnostic tests such as amniocentesis and chorionic villus sampling are done before the baby is born, which helps to check the chromosomal or genetic abnormalities in the baby. A bone marrow transplant can cure SCD. The transplant needs a donor who’s healthy, genetic match, such as a sibling. However, only about 18% of people with SCD have a compatible donor. In addition, there are complications and risks involved with a transplant.

Which distribution channel segment held the largest market share in the malaria and sickle cell disease treatment market?

The direct tender segment dominated the malaria treatment market and accounted for the largest market share in 2022.

Who are the key players in the malaria treatment market?

Cipla Ltd, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd among others are among the leading companies operating in the malaria and sickle cell disease treatment market.

What is the regional market scenario of the malaria treatment market?

Malaria and sickle cell disease treatment market is segmented by countries comprising of North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

Which treatment segment held the largest market share in the malaria and sickle cell disease treatment market?

The originators segment dominated the sickle cell disease treatment market and accounted for the largest market share in 2022. However, the vaccine segment dominated the malaria treatment market and accounted for the largest market share in 2022.

Which route of administration segment led the malaria and sickle cell disease treatment market?

Based on route of administration, the oral segment took the forefront leaders in the worldwide market by accounting largest share in 2022 and is expected to continue to do so till the forecast period.

The List of Companies - Malaria and Sickle Cell Disease Treatment Market

  1. Cipla Ltd
  2. Pfizer Inc
  3. Sun Pharmaceutical Industries Ltd
  4. Sanofi SA
  5. GSK Plc
  6. Novartis AG
  7. Pfizer Inc
  8. Emmaus Life Sciences Inc
  9. AdvaCare Pharma USA LLC
  10. VLP Therapeutics LLC
  11.  Lupin Ltd

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports